These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10682965)

  • 1. Dorzolamide and corneal recovery from edema in patients with glaucoma or ocular hypertension.
    Giasson CJ; Nguyen TQ; Boisjoly HM; Lesk MR; Amyot M; Charest M
    Am J Ophthalmol; 2000 Feb; 129(2):144-50. PubMed ID: 10682965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor.
    Wilkerson M; Cyrlin M; Lippa EA; Esposito D; Deasy D; Panebianco D; Fazio R; Yablonski M; Shields MB
    Arch Ophthalmol; 1993 Oct; 111(10):1343-50. PubMed ID: 8216014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dorzolamide on corneal endothelial function in normal human eyes.
    Egan CA; Hodge DO; McLaren JW; Bourne WM
    Invest Ophthalmol Vis Sci; 1998 Jan; 39(1):23-9. PubMed ID: 9430541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group.
    Lass JH; Khosrof SA; Laurence JK; Horwitz B; Ghosh K; Adamsons I
    Arch Ophthalmol; 1998 Aug; 116(8):1003-10. PubMed ID: 9715679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata.
    Wirtitsch MG; Findl O; Heinzl H; Drexler W
    Arch Ophthalmol; 2007 Oct; 125(10):1345-50. PubMed ID: 17923541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central corneal thickness in the European Glaucoma Prevention Study.
    ; Pfeiffer N; Torri V; Miglior S; Zeyen T; Adamsons I; Cunha-Vaz J
    Ophthalmology; 2007 Mar; 114(3):454-9. PubMed ID: 17126403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central corneal thickness in normal, glaucomatous, and ocular hypertensive eyes.
    Herndon LW; Choudhri SA; Cox T; Damji KF; Shields MB; Allingham RR
    Arch Ophthalmol; 1997 Sep; 115(9):1137-41. PubMed ID: 9298054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Dorzolamide Comparison Study Group.
    Rusk C; Sharpe E; Laurence J; Polis A; Adamsons I
    Clin Ther; 1998; 20(3):454-66. PubMed ID: 9663361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irreversible corneal decompensation in patients treated with topical dorzolamide.
    Konowal A; Morrison JC; Brown SV; Cooke DL; Maguire LJ; Verdier DV; Fraunfelder FT; Dennis RF; Epstein RJ
    Am J Ophthalmol; 1999 Apr; 127(4):403-6. PubMed ID: 10218692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
    Boyle JE; Ghosh K; Gieser DK; Adamsons IA
    Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Michaud JE; Friren B;
    Am J Ophthalmol; 2001 Aug; 132(2):235-43. PubMed ID: 11476685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness -- a cross-sectional study on 403 eyes].
    Viestenz A; Martus P; Schlötzer-Schrehardt U; Langenbucher A; Mardin CY
    Klin Monbl Augenheilkd; 2004 Sep; 221(9):753-6. PubMed ID: 15459842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension.
    Balfour JA; Wilde MI
    Drugs Aging; 1997 May; 10(5):384-403. PubMed ID: 9143858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension.
    Gugleta K
    Curr Med Res Opin; 2010 Jun; 26(6):1255-67. PubMed ID: 20350146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of contact lens induced corneal edema on Goldmann applanation tonometry measurements.
    Hamilton KE; Pye DC; Hali A; Lin C; Kam P; Ngyuen T
    J Glaucoma; 2007 Jan; 16(1):153-8. PubMed ID: 17224766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects.
    Nesher R; Ticho U
    Isr Med Assoc J; 2003 Apr; 5(4):260-3. PubMed ID: 14509130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of dorzolamide on corneal endothelium.
    Inoue K; Okugawa K; Oshika T; Amano S
    Jpn J Ophthalmol; 2003; 47(2):129-33. PubMed ID: 12738544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata.
    Wirtitsch MG; Findl O; Kiss B; Petternel V; Heinzl H; Drexler W
    Arch Ophthalmol; 2003 May; 121(5):621-5. PubMed ID: 12742838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of dorzolamide on corneal thickness, endothelial cell count and corneal sensibility.
    Kaminski S; Hommer A; Koyuncu D; Biowski R; Barisani T; Baumgartner I
    Acta Ophthalmol Scand; 1998 Feb; 76(1):78-9. PubMed ID: 9541439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability in hypoxia-induced corneal swelling is associated with variability in corneal metabolism and endothelial function.
    Nguyen T; Soni PS; Brizendine E; Bonanno JA
    Eye Contact Lens; 2003 Apr; 29(2):117-25. PubMed ID: 12695717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.